A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: A report on the first-year biochemical response;Hipofrakcionuota ir įprastai frakcionuota trimate konformine neišplitusio prostatos vežio spinduline terapija. Pirmųjų metų biocheminio atsako įvertinimas

Medicina

Volumn 45, Issue 6, 2009, Pages 469-475

  Norkus, Darius ^a   Miller, Albert ^b   Plieskiene, Aista ^a   Janulionis, Ernestas ^a   Valuckas, Konstantinas Povilas ^a  

^a Department of Radiotherapy ^*  (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Biochemical response; Hypofractionation; Prostate cancer; Radiotherapy

Indexed keywords

EID: 70349501635     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina45060061     Document Type: Article

References (25)

1. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000;55:85-90.
2. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507-512.
3. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.
4. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, Huizenga H, van Lin EN, Schimmel EC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006;64:5343-5345.
5. Haustermans K, Fowler JF. A comment on proliferation rates in human prostate cancer [Letter]. Int J Radiat Oncol Biol Phys 2000;48:297.
6. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-1101.
7. Fowler JF, Chappell RJ, Ritter MA. Is the α/β ratio for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50: 1021-1031.
8. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio) comparable to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13.
9. Joiner MC, Bentzen SM, Baumann M. Time-dose relationships: the linear-quadratic approach and the model in clinical practice. In: Steel GG, editor. Basic clinical radiobiology. 3rd ed. London: Arnold; 2002. p. 120-146.
10. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
11. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Shortcourse intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-1993.
12. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol BiolPhys 2007;63:1424-1430.
13. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe JE, Kanai T, et al. Hypofractionated radiotherapy with carbon ions beams for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63: 1153-1160.
14. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Cancer J 2003;9:268-276.
15. Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006;80:78-81.
16. Ritter MA, Forman JD, Kupelian PA, Petereit DG, Lawton C, Walker W, et al. A Phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 69:S174.
17. Junius S, Haustermans K, Bussels B, Oyen R, Vanstraelen B, Depuydt T, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer: results from a phase I/II feasibility study. Radiat Oncol 2007;2:29-36.
18. Martin JM, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M. A prospective study of hypofractionated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:35-36.
19. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69(4):1084-1089.
20. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.4 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-1105.
21. Lukka H, Hayter C, Warde P, Morris J, Julian J, Gospodarowicz M. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:S126.
22. Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2003;55:943-955.
23. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-526.
24. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostatespecific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002;53(2):297-303.
25. Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 2006;66(1): 20-24.